Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Chirurgia Endocrina e Metabolica
Roma, 00168, Italy
Location contact
Marco Raffaelli
CONTACT
Marco Raffaelli
PRINCIPAL_INVESTIGATOR
Maria Rosaria Magurano
CONTACT
NCT Number: NCT06556459
Patients with obesity who are candidates for bariatric surgery may exhibit high rates of psychological symptoms, mostly anxiety and depression, and even full-blown mental disorders. The etiopathogenesis of this association has been variously investigated, and among the various factors, the presence of systemic inflammation, even if low-grade, seems to be an underlying mechanism for both conditions. These associations have been shown to have a significant impact from both a clinical perspective and regarding the outcomes of the surgery itself . Worse outcomes have been described in individuals with anxiety-depressive syndromes or mood disorders. However, additional impacts on treatment can also result from the presence of dysfunctional personality traits and early traumatic experiences (reported in about 50% of individuals with severe/pathological obesity), which, in turn, correlate with pathological eating behaviors in a high percentage of cases.
Studies conducted in various countries show that about 40% of all patients undergoing bariatric surgery have at least one psychiatric diagnosis, with depressive disorders, anxiety disorders, and eating disorders being the three most common diagnoses
Most studies on bariatric patients have focused on factors predisposing to severe obesity or predictive of surgical outcomes and post-surgery progress, but often lack a more precise psychological and psychopathological characterization of this patient population. Targeted studies with a longitudinal design that include long-term post-surgery follow-up are necessary to clarify the actual role of these factors as well as their interaction with other pathophysiological mechanisms involved in the clinical presentation and response to various treatment strategies. Identifying new therapeutic targets during the preoperative evaluation process could, in fact, contribute to improving clinical and post-surgical outcomes. Despite bariatric surgery demonstrating a positive short-term impact on weight-related comorbidities and functioning levels, particularly in social relationships, the emergence of unique and peculiar psychosocial problems and/or concerns in the postoperative follow-up has been reported. In a 10-year longitudinal study, a significant increase in mental health service access was observed following bariatric surgery, especially among those with a positive psychiatric history before the surgery.
Besides weight loss, surgical outcomes should include improvements in metabolic status and medical comorbidities, increased quality of life, and better psychosocial and behavioral functioning. Even in a patient with excellent postoperative weight loss, psychosocial problems such as disruptions in interpersonal relationships, body image dissatisfaction, substance use, or suicidal ideation may arise.
Therefore, this study aims to investigate the sociodemographic, clinical, personality, psychological, and psychopathological characteristics of patients with severe/pathological obesity requesting bariatric surgery through a baseline assessment and, if applicable, at six and twelve months post-surgery.
Trial opening soon.
Get Notified18 year–65 year
All sexes
Observational
Roma, 00168, Italy
Marco Raffaelli
CONTACT
Marco Raffaelli
PRINCIPAL_INVESTIGATOR
Maria Rosaria Magurano
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The patient performs:
Time frame: 1 year
Evaluation of changes in anxiety and depressive symptoms from baseline to one year after bariatric surgery with Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 Questionnaire (GAD-7), Beck's Depression Inventory (BDI-II) and State-Trait Anxiety Inventory (STAI Y).
GAD - 7:
0 - 4: minimal 5 - 9: mild 10 - 14: moderate 15 - 21: severe
PHQ - 9:
0 - 4: minimal 5 - 9: mild 10 - 14: moderate 15 - 19: moderately severe 20 - 27: severe
BDI-II:
< 7: none 8 - 17: mild 18 - 24: moderate >25: severe
STAI-Y1/Y2:
20 - 37: none or minimal 38 - 44: moderate 45 - 80: severe
Time frame: 6 months
Interim evaluation of anxiety and depressive symptoms at six months after bariatric surgery with Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 Questionnaire (GAD-7), Beck's Depression Inventory (BDI-II) and State-Trait Anxiety Inventory (STAI Y).
GAD - 7:
0 - 4: minimal 5 - 9: mild 10 - 14: moderate 15 - 21: severe
PHQ - 9:
0 - 4: minimal 5 - 9: mild 10 - 14: moderate 15 - 19: moderately severe 20 - 27: severe
BDI-II:
< 7: none 8 - 17: mild 18 - 24: moderate >25: severe
STAI-Y1/Y2:
20 - 37: none or minimal 38 - 44: moderate 45 - 80: severe
Time frame: 1 year
Evaluation of changes in other psychological and psychopathological state dimensions from baseline to one year after bariatric surgery with Short Form Health Survey - 36 (SF-36), Perceived Stress Scale (PSS), Eating Disorder Examination Questionnaire (EDE-Q 6), Binge Eating Scale (BES), Clinical Impairment Assessment Questionnaire (CIA 3.0), Clinical Outcomes in Routine Evaluation - Outcome Measure (CORE-OM).
SF-36:
The score ranges from 0 (negative health) to 100 (positive health).
PSS:
0-13: low stress 14-26: moderate stress 27-60: high perceived stress
EDE-Q 6:
> 2,8: clinically significant
BES:
<17: improbable 17-27: possible >27: possible
CIA 3.0:
The resulting scores range from 0 to 48, where a higher score indicates a higher level of secondary psychosocial impairment.
CORE-OM:
<0,6: healthy 0,6-1: low 1-1,5: mild 1,5-2: moderate 2-2,5: moderately severe >2,5: severe
Time frame: 6 months
Interim evaluations after six months of changes in other psychological and psychopathological state dimensions as per clinical practice.
It will be used Short Form Health Survey - 36 (SF-36), Perceived Stress Scale (PSS), Eating Disorder Examination Questionnaire (EDE-Q 6), Binge Eating Scale (BES), Clinical Impairment Assessment Questionnaire (CIA 3.0), Clinical Outcomes in Routine Evaluation - Outcome Measure (CORE-OM).
SF-36:
The score ranges from 0 (negative health) to 100 (positive health).
PSS:
0-13: low stress 14-26: moderate stress 27-60: high perceived stress
EDE-Q 6:
> 2,8: clinically significant
BES:
<17: improbable 17-27: possible >27: possible
CIA 3.0:
The resulting scores range from 0 to 48, where a higher score indicates a higher level of secondary psychosocial impairment.
CORE-OM:
<0,6: healthy 0,6-1: low 1-1,5: mild 1,5-2: moderate 2-2,5: moderately severe >2,5: severe
Time frame: 6 months
Evaluation of the variation in global functioning levels from baseline at six months after bariatric surgery with Difficulties in Emotion Regulation Scale (DERS), Barratt Impulsiveness Scale (BIS 11), Connor-Davidson Resilience Scale (CD-RISC) and Childhood Trauma Questionnaire (CTQ-SF).
DERS:
Higher scores suggest greater problems with emotion regulation
BIS-11:
30-49: low 50-69: mild 70-89: severe 90-120: extremely severe
CD-RISC:
A higher score indicates a higher level of resilience
CTQ-SF:
This questionnaire measures five types of abuse. For each type of childhood trauma, the higher the score is, the greater the severity of abuse for that scale.
Time frame: one year
Evaluation of the variation in global functioning levels from baseline at one year after bariatric surgery with Difficulties in Emotion Regulation Scale (DERS), Barratt Impulsiveness Scale (BIS 11), Connor-Davidson Resilience Scale (CD-RISC) and Childhood Trauma Questionnaire (CTQ-SF).
DERS:
Higher scores suggest greater problems with emotion regulation
BIS-11:
30-49: low 50-69: mild 70-89: severe 90-120: extremely severe
CD-RISC:
A higher score indicates a higher level of resilience
CTQ-SF:
This questionnaire measures five types of abuse. For each type of childhood trauma, the higher the score is, the greater the severity of abuse for that scale.
Time frame: six months
Evaluation of the variation of the quality of life at six months after bariatric surgery with Short Form Health Survey - 36 (SF-36).
SF-36:
The score ranges from 0 (negative health) to 100 (positive health).
Time frame: 1 year
Evaluation of the variation of the quality from baseline to one year after bariatric surgery with Short Form Health Survey - 36 (SF-36).
SF-36:
The score ranges from 0 (negative health) to 100 (positive health).
Time frame: 1 year
Identification of correlation between psychological and psychopathological trait dimensions and metabolic and inflammatory correlates that predict response to bariatric surgery interventions.
It will be measured the variation of the metabolic and inflammatory correlates from baseline to one year after bariatric surgery.
It will be considered: complete blood count with leukocyte count; C-reactive Protein (PCR); Erythrocyte sedimentation rate (VES); fibrinogen; magnesium; calcium; phosphorus; parathyroid hormone (PTH); vitamin D; uric acid; carbohydrate and lipid profile (glucose, total and HDL cholesterol, triglycerides);
Contact information is provided by the study sponsor or research team.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Other
Psychological and Psychopathological Characteristics of Patients With Severe or Pathological Obesity Candidates for Bariatric Surgery
Acronym: PSICOBAR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07437976
Body Weight, Nutrition Disorders
Research Triangle Park, North Carolina, United States
View Trial DetailsNCT07478653
Body Weight, Dental Care for Children
Lexington, Kentucky, United States
View Trial DetailsNCT05713799
Body Weight, Glucose Metabolism Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT07388537
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial Details